Is a Biosimilar Interchangeable With an Originator?

Affiliations

¹ Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada.
² Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.

Comment

Reena Khanna et al. Gastroenterology. 2017 Oct.

. 2017 Oct;153(4):1160-1162.

doi: 10.1053/j.gastro.2017.08.049. Epub 2017 Sep 1.

¹ Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada.
² Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.

No abstract available

Comment on

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.